Sangamo Therapeutics Inc
SGMO0.538USD
-0.024-4.26%
交易中 （美東）報價延遲15分鐘
121.18M總市值
虧損本益比TTM
關於 Sangamo Therapeutics Inc 公司
Sangamo Therapeutics, Inc. 是一家基因藥物公司，正在開發用於治療神經系統疾病的藥物。該公司的神經病學臨牀前開發專注於兩個領域：開發表觀遺傳調控療法以治療嚴重的神經系統疾病，以及開發新型工程腺相關病毒 (AAV) 衣殼以將其療法遞送至預期的神經系統目標。該公司的鋅指表觀遺傳調節劑非常適合潛在地治療神經系統疾病，其衣殼發現平臺正在將遞送範圍擴展到鞘內遞送衣殼之外，包括中樞神經系統。其臨牀階段候選產品是 Isaralgagene civaparvovec（也稱爲 ST-920），這是其全資擁有的用於治療法布里病的基因治療候選產品，以及其全資擁有的用於預防 HLA-A2 不匹配腎移植中免疫介導排斥的 CAR-Treg 細胞治療候選產品 TX200。
公司簡介
公司代碼SGMO
公司名稱Sangamo Therapeutics Inc
上市日期Apr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
員工數量183
證券類型Ordinary Share
年結日Apr 06
公司地址501 Canal Blvd.
城市RICHMOND
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94084
電話15109706000
網址https://www.sangamo.com/
公司代碼SGMO
上市日期Apr 06, 2000
CEODr. Alexander D. Macrae, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
350.46K
-8.33%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
344.06K
-8.48%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
205.78K
-3.16%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. John H. Markels, Ph.D.
Dr. John H. Markels, Ph.D.
Independent Director
Independent Director
--
--
Ms. Louise Wilkie
Ms. Louise Wilkie
Investor Relations
Investor Relations
--
--
Ms. H. Stewart Parker
Ms. H. Stewart Parker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Ms. Nathalie Dubois- Stringfellow, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Scott B. Willoughby
Mr. Scott B. Willoughby
Chief Legal Officer & Corporate Secretary
Chief Legal Officer & Corporate Secretary
350.46K
-8.33%
Ms. Prathyusha Duraibabu, CPA
Ms. Prathyusha Duraibabu, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
344.06K
-8.48%
Dr. Gregory Davis, Ph.D.
Dr. Gregory Davis, Ph.D.
Head of Research & Technology
Head of Research & Technology
205.78K
-3.16%
Ms. Margaret A. Horn, J.D.
Ms. Margaret A. Horn, J.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Courtney Beers, Ph.D.
Dr. Courtney Beers, Ph.D.
Independent Director
Independent Director
76.40K
+48.64%
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
FY2024
FY2023
暫無數據
地區USD
名稱
營收
佔比
United States
57.80M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
3.95%
Wasatch Global Investors Inc
2.89%
BlackRock Institutional Trust Company, N.A.
1.91%
Biogen Inc
1.37%
Renaissance Technologies LLC
1.33%
Other
88.55%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
3.95%
Wasatch Global Investors Inc
2.89%
BlackRock Institutional Trust Company, N.A.
1.91%
Biogen Inc
1.37%
Renaissance Technologies LLC
1.33%
Other
88.55%
股東類型
持股股東
佔比
Investment Advisor
9.68%
Investment Advisor/Hedge Fund
6.21%
Hedge Fund
5.94%
Individual Investor
1.42%
Corporation
1.37%
Research Firm
0.90%
Pension Fund
0.09%
Bank and Trust
0.02%
Other
74.37%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
348
61.31M
25.80%
-60.01M
2025Q1
404
58.78M
24.86%
-65.68M
2024Q4
408
67.57M
32.39%
-54.70M
2024Q3
411
61.90M
29.72%
-75.37M
2024Q2
422
105.29M
52.02%
-52.38M
2024Q1
424
122.66M
61.96%
-20.13M
2023Q4
430
104.60M
58.76%
-36.84M
2023Q3
436
126.62M
71.56%
-23.29M
2023Q2
448
137.28M
80.06%
-15.05M
2023Q1
460
145.31M
88.52%
+4.38M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
9.37M
3.95%
--
--
Mar 31, 2025
Wasatch Global Investors Inc
6.87M
2.89%
-2.36M
-25.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.55M
1.91%
+2.82K
+0.06%
Mar 31, 2025
Biogen Inc
3.25M
1.37%
-11.40M
-77.82%
Aug 14, 2024
Renaissance Technologies LLC
3.17M
1.33%
+83.23K
+2.70%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.28M
0.96%
+71.60K
+3.24%
Mar 31, 2025
GSA Capital Partners LLP
966.20K
0.41%
+934.65K
+2962.16%
Mar 31, 2025
Point72 Asset Management, L.P.
2.00M
0.84%
-272.51K
-12.00%
Mar 31, 2025
Ikarian Capital LLC
1.86M
0.78%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.81M
0.76%
+1.52M
+535.12%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.52%
iShares Neuroscience and Healthcare ETF
0.32%
Global X Genomics & Biotechnology ETF
0.21%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR S&P Kensho New Economies Composite ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.52%
iShares Neuroscience and Healthcare ETF
佔比0.32%
Global X Genomics & Biotechnology ETF
佔比0.21%
Invesco RAFI US 1500 Small-Mid ETF
佔比0.01%
Fidelity Enhanced Small Cap ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Schwab U.S. Small-Cap ETF
佔比0%
SPDR S&P Kensho New Economies Composite ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
